secwatch / observer
8-K filed May 26, 2026, 4:48 PM ET ticker VKTX CIK 0001607678
other material confidence high sentiment neutral materiality 0.15

Viking Therapeutics annual meeting elects two Class II directors, ratifies auditor

Viking Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Viking Therapeutics, Inc. shareholders approved Approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement at the 2026-05-19 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-05-19
Exact text from the filing
Proposal No. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 30,045,938 12,763,135 401,396 36,879,063
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Viking Therapeutics, Inc. shareholders approved Elect J. Matthew Singleton and S. Kathryn Rouan, Ph.D. as Class II directors at the 2026-05-19 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-19
Exact text from the filing
Proposal No. 1. To elect the following nominees as Class II directors to serve until the Company’s 2029 annual meeting of stockholders or until such director’s respective successor is duly elected and qualified: Director Nominee Votes For Votes Withheld Broker Non-Votes J. Matthew Singleton 28,648,459 14,562,012 36,879,061 S. Kathryn Rouan, Ph.D. 21,960,203 21,250,268 36,879,061
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Viking Therapeutics, Inc. shareholders approved Ratify the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-19 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-19
Exact text from the filing
Proposal No. 2. To ratify the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 78,368,957 1,241,969 478,606
View on SEC.gov

Browse all shareholder votes →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-239535
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.